| Literature DB >> 26690730 |
M Masudur Rahman1, Uday C Ghoshal2, A H M Rowshon3, Faruque Ahmed1, Md Golam Kibria1, Mahmud Hasan4, Kok-Ann Gwee5, William E Whitehead6.
Abstract
BACKGROUND/AIMS: Functional gastrointestinal disorders (FGIDs), diagnosed by symptom-based criteria due to lack of biomarkers, need translatedvalidated questionnaires in different languages. As Bengali, the mother tongue of Bangladesh and eastern India, is the seventh most spoken language in the world, we translated and validated the Enhanced Asian Rome III questionnaire (EAR3Q) in this language.Entities:
Keywords: Bangladesh; Constipation; Dyspepsia; India; Irritable bowel syndrome
Year: 2016 PMID: 26690730 PMCID: PMC4819862 DOI: 10.5056/jnm15129
Source DB: PubMed Journal: J Neurogastroenterol Motil ISSN: 2093-0879 Impact factor: 4.924
FigureOutline of the process of translation validation of the Enhanced Asian Rome III questionnaire (EAR3Q) in Bengali language. GI, gastrointestinal.
Demographic and Clinical Parameters of Patients and Healthy Subjects Included in the Translation-validation Study
| Parameters | HS | IBS | FD | FC | |
|---|---|---|---|---|---|
| Number of subjects | 30 | 40 | 35 | 12 | |
| Age (median age [range], yr) | 29 (18–46) | 28 (18–65) | 30 (18–70) | 36 (18–70) | NS |
| Gender (male) | 23 (76.6%) | 36 (90.0%) | 22 (62.8%) | 10 (83.3%) | NS for all except FD vs IBS |
| Education | |||||
| Class I to X | 1 (3.3%) | 12 (30.0%) | 20 (57.2%) | 5 (41.7%) | |
| SSC/HSC | 5 (16.7%) | 13 (32.5%) | 8 (22.8%) | 5 (41.7%) | < 0.001 |
| Graduate/postgraduate | 19 (63.3%) | 13 (32.5%) | 7 (20.0%) | 2 (16.7%) | |
| Professionals/others | 5 (16.7%) | 2 (5.0%) | 0 (0.0%) | 0 (0.0%) | |
| Occupation | |||||
| Housewife | 2 (6.7%) | 4 (10.0%) | 9 (25.71%) | 2 (16.7%) | |
| Service sector | 24 (80.0%) | 12 (30.0%) | 16 (45.7%) | 7 (58.3%) | 0.001 |
| Business | 0 (0.0%) | 7 (17.5%) | 3 (8.6%) | 0 (0.0%) | |
| Others | 4 (13.3%) | 17 (42.5%) | 7 (20.0%) | 3 (25.0%) | |
| KS family income group (taka per month) | |||||
| > 22500 (KS group 1, 2) | 14 (46.7%) | 6 (15.0%) | 1 (2.9%) | 3 (25.0%) | |
| 22499-11236 (KS group 3, 4) | 9 (30.0%) | 16 (40.0%) | 21 (60.0%) | 3 (25.0%) | < 0.001 |
| < 11235 (KS group 5–7) | 7 (23.3%) | 18 (45.0%) | 13 (37.1%) | 6 (50.0%) | |
HS, healthy subjects; IBS, irritable bowel syndrome; FD, functional dyspepsia; FC, functional constipation; NS, not significant; SSC, secondary school certificate; HSC, higher school certificate; KS, Kuppuswamy’s.
1 US dollar = 80 taka in October 2015.
Diagnostic Performance, Sensitivity, and Specificity of Bengali Version of Enhanced Asian Rome III Questionnaires
| Diagnostic category (healthy vs FBDs) | Concordance between clinical and questionnaire-based diagnosis on initial visit | Sensitivity | Specificity |
|---|---|---|---|
| Healthy control (n = 30) | 30 | 100% | 100% |
| IBS (n = 40) | 40 | 100% | 100% |
| FD (n = 35) | 35 | 100% | 100% |
| FC (n = 12) | 9 | 75% | 100% |
FBDs, functional bowel diseases; IBS, irritable bowel syndrome; FD, functional dyspepsia; FC, functional constipation.
Diagnostic Performance, Test-retest Reliability of Bengali Version of Enhanced Asian Rome III Questionnaires
| Diagnostic category (healthy vs FBDs) | Concordance between clinical and questionnaire-based diagnosis on initial visit | Concordance between clinical and questionnaire-based diagnosis on 14th day visit | Kappa values (EAR3Q based diagnosis at initial and 2-week follow-up) |
|---|---|---|---|
| Healthy control (n = 30) | 30 | 30 | 1.00 |
| IBS (n = 40) | 40 | 40 | 1.00 |
| FD (n = 35) | 35 | 35 | 1.00 |
| FC (n = 12) | 9 | 10 | 0.83 |
FBDs, functional bowel diseases; EAR3Q, Enhanced Asian Rome III questionnaire; IBS, irritable bowel syndrome; FD, functional dyspepsia; FC, functional constipation.
Overlap Between Different Functional Bowel Diseases Detected by Bengali Version of Enhanced Asian Rome III Questionnaires During Validation Study
| Diagnostic category | First visit | Second visit at 2 weeks | ||
|---|---|---|---|---|
|
|
| |||
| Concomitant FBD (overlap) | n (%) | Concomitant FBD (overlap) | n (%) | |
| IBS (n = 40) | FD | 12 (30.0%) | FD | 12 (30.0%) |
| FD (n = 35) | IBS | 8 (22.8%) | IBS | 10 (28.5%) |
| FC | 3 (8.5%) | FC | 1 (2.9%) | |
| FC (n = 12) | FD | 1 (11.1%) | FD | 2 (20.0%) |
FBD, functional bowel disease; IBS, irritable bowel syndrome; FD, functional dyspepsia; FC, functional constipation.